A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children 2 to <12 Years of Age

The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 2 to <12 years of age.

开始日期2025-06-05

申办/合作机构

Bavarian Nordic A/S

NCT06007183

/ Active, not recruiting临床3期

A Long-term Follow-up Study to Evaluate Safety and Immunogenicity of a Chikungunya Virus Virus-like Particle Vaccine (PXVX0317) in Healthy Adults and Adolescents After Either a Single or Booster Vaccination Dosing Regimen

The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunogenicity of CHIKV VLP vaccine in adult and adolescent participants and to evaluate CHIKV VLP booster vaccine induced serum neutralizing antibody (SNA) response at 3, 4, or 5 years post-initial CHIKV VLP vaccination.

开始日期2023-08-30

申办/合作机构

Bavarian Nordic A/S

NCT05349617

/ Completed临床3期

A Phase 3 Safety and Immunogenicity Trial of the VLP-Based Chikungunya Virus Vaccine PXVX0317 in Adults ≥65 Years of Age

The purpose of this phase 3, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity to PXVX0317 in adults ≥65 years of age.

开始日期2022-05-12

申办/合作机构

Bavarian Nordic A/S

[+1]

100 项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的临床结果

登录后查看更多信息

100 项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的转化医学

登录后查看更多信息

100 项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的专利（医药）

登录后查看更多信息

157

项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的文献（医药）

2025-12-31·Expert Review of Vaccines

Virus-like particles: a versatile and effective vaccine platform

Review

作者: Bachmann, Martin F. ; Lienert, Florian ; Schwarz, Tino F. ; van Damme, Pierre

INTRODUCTION:

Traditional live-attenuated or inactivated vaccines have limitations, including risks associated with uncontrolled replication, reduced immunogenicity, or production complexities. To address these issues, alternative platforms such as virus-like particles (VLPs) have been developed.

AREAS COVERED:

VLPs are self-assembling structures composed of viral proteins that mimic native viruses but are noninfectious. This review provides an overview of their structure, design and manufacture that make them an attractive platform for vaccine development. We then discuss the clinical development of some recently approved VLP vaccines and those widely used in immunization programs, summarizing the clinical trial data that underpins their efficacy and safety profiles. Additionally, we explore VLP vaccines in late-stage clinical development for respiratory syncytial virus and human metapneumovirus.

EXPERT OPINION:

VLPs are a versatile and promising platform for vaccine development. Their ability to mimic native viruses while eliminating the risks associated with live vaccines positions them as an attractive platform for vaccine design. Currently approved VLP vaccines demonstrate that they can provide effective protection against a wide range of diseases. Advances in VLP design and production are likely to lead to highly effective vaccines, significantly contributing to global immunization efforts.

2025-04-01·LANCET

Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial

Article

作者: Warfield, Kelly L ; Jenkins, Victoria A ; Richardson, Jason S ; Tindale, Lauren C ; Muhammad, Sufia ; Bedell, Lisa ; Mendy, Jason ; Tredo, Sarah Royalty ; Loreth, Tobi ; Ajiboye, Patrick ; Ramanathan, Roshan ; Caso, Jorge T ; Anderson, Deborah M

BACKGROUND:

Chikungunya disease is a growing global public health concern. Vimkunya (previously chikungunya virus virus-like particle vaccine, previously PXVX0317) is a single-dose, pre-filled syringe for intramuscular injection. Here, we report safety, tolerability, and immunogenicity data for Vimkunya versus placebo in healthy adolescents and adults aged 12-64 years, and evaluate lot-to-lot consistency.

METHODS:

This pivotal phase 3, randomised, double-blind, placebo-controlled, parallel-group trial was done at 47 clinical trial sites in the USA. Eligible participants were healthy adolescents and adults aged 12-64 years. Participants were divided into three age strata (12-17 years, 18-45 years, and 46-64 years) within each site and randomly assigned (2:2:2:1) to receive one of three consecutively manufactured lots of Vimkunya or placebo (same excipient composition without chikungunya virus virus-like particle or aluminium hydroxide components) on study day 1. Neither participants, nor clinical site personnel, nor the funder knew participants' individual treatment assignments until all participants completed their involvement in the trial and the database was cleaned and locked. Participants attended a screening visit, followed by a day 1 visit that included random assignment, blood sample collection, and administration of a single dose of Vimkunya or placebo by intramuscular injection in the deltoid muscle. The coprimary endpoints were: the difference in chikungunya virus serum neutralising antibody seroreponse rate (vaccine minus placebo) at day 22; chikungunya virus serum neutralising antibody geometric mean titre (GMT) at day 22 for vaccine and placebo; and chikungunya virus serum neutralising GMT ratio at day 22 between all three pairs of vaccine lots (A:B, B:C, and A:C) in adults aged 18-45 years. The trial is registered with ClinicalTrials.gov, NCT05072080 and EudraCT, 2023-001124-42.

FINDINGS:

Between Sept 29, 2021, and Sept 23, 2022, 4215 participants were screened, of whom 3258 were eligible and enrolled (1667 [51·2%] female and 1591 [48·8%] male), and 3254 (99·9%) received either Vimkunya (n=2790) or placebo (n=464). The immunogenicity evaluable population included 2983 participants, of whom 2559 received Vimkunya and 424 received placebo. At day 22, 2503 (97·8%) of 2559 participants in the Vimkunya group had a seroresponse, compared with five (1·2%) of 424 participants in the placebo group for the immunogenicity evaluable population. The seroreponse rate difference was 96·6% (95% CI 95·0-97·5; p<0·0001). In the immunogenicity evaluable population, chikungunya virus serum neutralising antibody GMT at day 22 for the vaccine group was 1618 and for the placebo group was 7·9 (p<0·0001). At day 22, the serum neutralising GMT ratios for the pairs of lots (A:B, B:C, and A:C) were 0·98 (95% CI 0·85-1·14), 0·97 (0·84-1·12), and 0·95 (0·82-1·10), respectively. Vimkunya had a favourable safety profile; most adverse events were self-limiting and grade 1 or 2 in severity. The most common adverse events were injection site pain (656 [23·7%] of 2764 participants in the vaccine group), fatigue (551 [19·9%] of 2764), headache (498 [18·0%] of 2765), and myalgia (486 [17·6%] of 2764).

INTERPRETATION:

Vimkunya induces a rapid and robust immune response. These findings support the potential for this vaccine to protect individuals aged 12-64 years from disease caused by chikungunya virus.

FUNDING:

Emergent BioSolutions and Bavarian Nordic.

2025-04-01·Lancet Microbe

Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: an open-label, parallel-group, age-matched, sex-matched, phase 2 randomised controlled study

Article

作者: Mendy, Jason ; Liggett, Dani L ; Pierson, Benjamin C ; Ghosh, Neha ; Regules, Jason A ; Richardson, Jason S ; Warfield, Kelly L ; Gardner, Christina L ; Bedell, Lisa ; Burke, Crystal W ; Saunders, David ; Lee, Christine ; Hamer, Melinda J ; McCarty, James M ; Glass, Pamela J ; Haller, Jeannine M ; Royalty Tredo, Sarah ; Sanborn, Aaron D ; Gregory, Melissa K

BACKGROUND:

Immune responses to alphavirus vaccines might be impaired when heterologous alphavirus vaccines are administered sequentially. We aimed to compare immunogenicity and safety of a chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of heterologous alphavirus vaccines with alphavirus-naive controls in the USA.

METHODS:

In this open-label, parallel-group, age-matched, sex-matched, phase 2 randomised controlled trial, which was conducted at two clinical study sites in the USA, adults (aged 18-65 years) who had previously received an investigational Venezuelan equine encephalitis virus vaccine (previous alphavirus vaccine recipients; n=30) and sex-matched and age-matched alphavirus vaccine-naive controls (n=30) were intramuscularly administered one 40 μg dose of CHIKV VLP vaccine on day 1. Immunogenicity was based on serum neutralising antibodies assessed by an in-vitro luciferase-based anti-CHIKV NT₈₀ neutralisation assay. The primary immunogenicity endpoint, which was assessed in the immunogenicity evaluable population (CHIKV VLP-vaccinated participants who had no important protocol deviations, had not received a prohibited medication, and provided evaluable serum sample results for baseline and on day 22), was to compare the proportion of previous alphavirus vaccine recipients with the proportion of alphavirus vaccine-naive controls who reached seroconversion 21 days after vaccination (ie, study day 22) with a single dose of CHIKV VLP vaccine, based on a four-fold increase of CHIKV neutralising antibodies compared with baseline. The significance of the comparison of the two groups was assessed using Fisher's exact test. The proportion with seroconversion in each group is presented with 95% CIs calculated using the Wilson method. The difference and 95% CIs for this difference was calculated based on Newcombe hybrid score method. An ANOVA model was fit with log₁₀-transformed titre as the dependent variable, and study arm, age, and sex as predictors. Least squares means, difference, and 95% CIs were back-transformed and reported as geometric mean titres (GMTs). This trial is registered with ClinicalTrials.gov, NCT03992872.

FINDINGS:

Between Nov 20, 2019, and Jan 19, 2021, 60 participants (20 [33%] female and 40 [67%] male; 40 (67%) White; median age 47·0 years [IQR 13·5]), 30 previous alphavirus vaccine recipients and 30 alphavirus vaccine-naive controls, were enrolled, vaccinated with CHIKV VLP, and completed the trial. The anti-CHIKV neutralising antibody seroconversion rate at day 22 was 100% (95% CI 88·6-100) in both groups. GMTs peaked in previous alphavirus vaccine recipients and alphavirus vaccine-naive controls at day 22 (2032·5 [95% CI 1413·0-2923·6] and 2299·2 [1598·1-3307·8], respectively) and were similar between the groups on day 22 and all subsequent visits. A higher proportion of previous alphavirus vaccine recipients (93·3% [95% CI 78·7-98·2]) had a four-fold neutralising antibody increase at day 8 than did alphavirus vaccine-naive controls (66·7% [48·8-80·8]; p=0·021). There was no statistically significant difference in the incidence of solicited adverse events between the previous alphavirus vaccine recipients and alphavirus vaccine-naive controls (53·3% vs 40·0%, respectively), although the relatively small sample size of the trial limited the power to detect a significant difference, and there were no reported vaccine-related serious adverse events.

INTERPRETATION:

CHIKV VLP vaccine was well tolerated and similarly immunogenic in both alphavirus vaccine-naive participants and previous recipients of a heterologous alphavirus vaccine. There were no significant differences in adverse events between the groups. The results of this study support the use of CHIKV VLP vaccine in individuals with previous alphavirus vaccine exposure.

FUNDING:

Defense Health Program, Emergent Travel Health, and Bavarian Nordic A/S.

项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的新闻（医药）

2025-07-24

·FiercePharma

Bavarian Nordic confirms buyout talks with private equity firms amid new chikungunya threats

Bavarian Nordic confirmed Thursday that the company is in talks with private equity firms Nordic Capital and Permira about a potential takeover bid for the Danish drugmaker. Just as new outbreaks of chikungunya threaten to become another epidemic, Bavarian Nordic, maker of a vaccine against the mosquito-borne virus, has entered discussions of a potential buyout.Bavarian Nordic confirmed Thursday that the company is in talks with private equity firms Nordic Capital and Permira about a potential takeover bid for the Danish drugmaker.The discussions remain ongoing, and “there can be no certainty” as to whether any offer will be made and its timing, Bavarian said. Such an acquisition would take the Nasdaq Copenhagen-listed company private.The company’s stock price rose more than 21% late Thursday morning. Bavarian Nordic makes Vimkunya, a chikungunya vaccine approved by the U.S. FDA in April for protection among individuals 12 years of age and above. The company in June started a phase 3 trial of the shot in children 2 to 11 years of age, with results expected in the first half of 2028.Revelation of the deal talks emerged just as the World Health Organization (WHO) warned on Tuesday that urgent actions are needed to prevent the escalation of a new wave of chikungunya outbreaks.“We are seeing history repeating itself,” Diana Rojas Alvarez, a medical officer at the WHO and arbovirus team lead with the organization, said during a press briefing, referring to the 2004-05 chikungunya epidemic, as quoted by Reuters.Outbreaks have been spotted in the same Indian Ocean areas that were previously hit, including La Reunion, Mayotte and Mauritius, spreading to Madagascar, Somalia and Kenya. Southeast Asian countries and France have reported alarming transmissions. And China is experiencing the country’s biggest chikungunya outbreak since the virus first emerged in the mainland about two decades ago. Valneva’s Ixchiq, another FDA-approved chikungunya shot, is cleared only in adults. The FDA and the Centers for Disease Control and Prevention recently paused Ixchiq’s use in people 60 years of age and older following reports of some serious adverse events, including two deaths.To expand access to Vimkunya, Bavarian has partnered with Biological E to manufacture and supply the vaccine to endemic low- and middle-income countries.This isn’t the first time Bavarian has found itself at the forefront of a global health crisis. The company has been supplying global governments, including the U.S., with its mpox and smallpox vaccine Jynneos, which played an important countermeasure role during a 2022 mpox outbreak.As of July 9, Bavarian has secured more than 3 billion Danish kroner ($473 million) worth of Jynneos contracts for public preparedness efforts in 2025. In 2024, Bavarian Nordic reported 5.72 billion Danish kroner (about $900 million) in revenue. In the first quarter of 2025, revenue surged 62% to 1.35 billion Danish kroner.As of early May, the company was expecting Vimkunya's full-year revenue to fall between 50 million Danish kroner and 100 million Danish kroner in 2025.Meanwhile, Nordic Capital appears to be in an acquisitive mood, targeting the healthcare industry. The private equity firm recently acquired healthcare data analytics company Arcadia after bowing out of potential buyout talks with biotech platform entity PureTech Health.

并购上市批准疫苗临床3期

2025-07-24

·EndPoints

Vaccine maker Bavarian Nordic confirms it's in potential takeover talks

Riding a recent wave of wins, Bavarian Nordic confirmed on Thursday that it has “been in discussions” with private equity firms over a potential takeover offer. The Danish vaccine maker said it has been in talks with Nordic Capital and Permira. The conversations are ongoing and there is “no certainty as to whether any offer” will actually be made, Bavarian said in a news release. Timing and terms of a potential offer are also unknown. Spokespersons for Bavarian Nordic, Permira and Nordic Capital all declined to comment. A takeover would come after a string of positive updates from the company. Earlier this month, Bavarian Nordic said it nabbed another smallpox/mpox vaccine supply contract with an undisclosed European country. Last month, it sold a priority review voucher for $160 million thanks to an FDA greenlight for its chikungunya vaccine in February. Bavarian’s market cap was $3 billion on Thursday, following news of the potential takeover. The company has a suite of approved vaccines for smallpox and an mpox vaccine, as well as vaccines for travel health. The company has said it expects little impact from potential pharma tariffs that the US government is mulling. Bavarian Nordic has a commercial site and an R&D manufacturing facility in the US. “We just have to wait and see what concrete things come through, and then we’ll have to respond,” CEO Paul Chaplin told Endpoints News in March. Bavarian said earlier this month that it anticipates total 2025 revenue of DKK 5.7 billion to 6.7 billion DKK (about $899 million to $1.05 billion). Earlier this week, another vaccine company inked a deal. Sanofi said it would pay $1.15 billion upfront for early-stage vaccine maker Vicebio. Permira’s healthcare portfolio includes PharmaCord, Kedrion Biopharma, Neuraxpharm and others. The investment firm has deployed more than €5 billion ($5.8 billion) across more than 20 companies in the sector, according to a June press release . Nordic Capital, meanwhile, was rejected by PureTech Health earlier this year. The firm’s healthcare portfolio includes Advanz Pharma and LEO Pharma, among others.

疫苗优先审批并购

2025-07-22

·GlobeNewswire-Health Care

Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine

COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older. The application screening acceptance by the Directorate confirms that the New Drug Submission is complete and begins a standard review procedure, potentially supporting approval of the vaccine in the first half of 2026. The New Drug Submission is based on the data, which also supported the recent US, EU and UK approvals of the vaccine, including results from two phase 3 clinical trials which enrolled more than 3,500 healthy individuals 12 years of age and older. The studies met their primary endpoints, with results showing that 21 days after vaccination, the vaccine induced neutralizing antibodies in up to 97.8% of the vaccinated individuals, (97.8% in individuals 12 years to 64 and 87.3% in over 65 year olds). The key secondary endpoint of seroresponse rate at day 8 post vaccination was 46.6% and 96.8% at day 15 in the 12-64 year old population and 82.3% at day 15 for the over 65 population. The vaccine was well-tolerated and vaccine-related adverse events were mainly mild or moderate in nature. The most common side effects were pain at the injection site, fatigue, headache, and muscle pain1,2. Paul Chaplin, President and CEO of Bavarian Nordic, said: “The regulatory submission and acceptance by Health Canada represents yet another highlight in our efforts to expand access to our chikungunya vaccine across the globe. Pending approval, this vaccine will further strengthen our offering for Canadians seeking protection against serious diseases when traveling the world.” About CHIKV VLPCHIKV VLP is a vaccine for the prevention of chikungunya disease in individuals aged 12 years and above. It is designed to induce a robust seroresponse, with protective immunity starting to develop as early as 1 week after vaccination. Pending regulatory approval, CHIKV VLP vaccine will be available in a prefilled syringe. CHIKV VLP does not contain viral genetic material and is therefore non-infectious and unable to cause disease, ensuring a broad range of people can benefit from vaccination. The vaccine was approved by the U.S. Food and Drug Administration (FDA) and the European Commission in February 20253,4 and the United Kingdom in May 20255 under the trade name VIMKUNYA®6. About chikungunyaChikungunya is a mosquito-borne disease caused by the chikungunya virus (CHIKV). In the past 20 years, the virus has emerged across several regions in Asia, Africa, and the Americas, including many popular travel destinations, often causing large unpredictable outbreaks. Since its discovery, CHIKV has been identified in more than 110 countries, with evidence of transmission confirmed in more than 50 countries over the past five years7. Chikungunya typically presents with acute symptoms, including fever, rash, fatigue, headache, and often severe and incapacitating joint pain. Most patients recover within 1-2 weeks, but 30-40% of those affected may develop chronic arthritis that can last for months or even years8. In 2024, 620,000 cases of chikungunya and over 200 deaths were reported worldwide9. Recent data suggest that chikungunya is severely underreported and often misdiagnosed as dengue fever due to a similar symptom profile10. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com. Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors:Europe: Rolf Sass Sørensen, Vice President Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 43US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600 Contact media:Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: +45 53 88 06 03 1 Richardson JS, et al. Chikungunya Virus VLP Vaccine: Phase 3 Trial in Adolescents and Adults. medRxiv 2024.10.11.24315179. 2 Tindale LC, et al. Chikungunya Virus VLP Vaccine: Phase 3 Trial in Adults ≥65 Years of Age. medRxiv 2024.10.10.24315205. 3 Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older. https://www.bavarian-nordic.com/investor/news/news.aspx?news=7053 4 Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older. https://www.bavarian-nordic.com/investor/news/news.aspx?news=7056 5 Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United Kingdom. https://www.bavarian-nordic.com/investor/news/news.aspx?news=7132 6 Marketed as VIMKUNYA™ in the US. Marketed as VIMKUNYA® in EU and the United Kingdom. 7 Centers for Disease Control and Prevention. Areas at Risk for Chikungunya. https://www.cdc.gov/chikungunya/data-maps/index.html. 8 European Centre for Disease Prevention and Control. Chikungunya virus disease. https://www.ecdc.europa.eu/en/chikungunya-virus-disease. 9 European Centre for Disease Prevention and Control. Chikungunya virus disease case notification rate per 100 000 population, January 2024-December 2024. https://www.ecdc.europa.eu/en/publications-data/chikungunya-virus-disease-case-notification-rate-100-000-population-january-2024. 10 Ribas Freitas AR, Pinheiro Chagas AA, Siqueira AM, Pamplona de Góes Cavalcanti L. How much of the current serious arbovirus epidemic in Brazil is dengue and how much is chikungunya? Lancet Reg Health Am. 2024 Apr 30;34:100753. doi: 10.1016/j.lana.2024.100753. PMID: 38711542; PMCID: PMC11070701. Attachment 2025-07-22-en

临床3期临床结果疫苗上市批准

100 项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
基孔肯雅热	美国	Bavarian Nordic A/S	2025-02-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03992872 (Pubmed \| Lancet Microbe)	临床2期	甲病毒感染	60	Previous alphavirus vaccine recipients	鏇鑰鏇齋憲築艱齋醖觸(鹹廠範壓鹹獵淵糧製鏇) = There was no statistically significant difference in the incidence of solicited adverse events between the previous alphavirus vaccine recipients and alphavirus vaccine-naive controls (53.3% vs 40.0%, respectively), although the relatively small sample size of the trial limited the power to detect a significant difference, and there were no reported vaccine-related serious adverse events 艱遞積構鏇簾醖鹹艱鏇 (網觸醖觸壓糧醖觸糧製 )	积极	2025-04-01
				Alphavirus vaccine-naive controls
NCT05072080 (FDA_CBER) 人工标引	临床3期	基孔肯雅热	-	VIMKUNYA	選觸構夢顧觸鹽膚範蓋(壓獵淵鬱襯襯構膚夢鹽) = 夢顧壓壓築淵淵築膚齋餘廠襯衊廠構製壓襯鹽 (鑰願衊遞範襯窪鏇壓鑰, 1504.1 ~ 1695.6) 更多	积极	2025-02-14
				Placebo	選觸構夢顧觸鹽膚範蓋(壓獵淵鬱襯襯構膚夢鹽) = 鑰積鹽網鏇憲夢觸廠製餘廠襯衊廠構製壓襯鹽 (鑰願衊遞範襯窪鏇壓鑰, 7.0 ~ 8.8) 更多
NCT05349617 (FDA_CBER) 人工标引	临床3期	基孔肯雅热	-	VIMKUNYA	蓋憲製糧衊願餘憲選鑰(構鹽網鬱觸遞築蓋鏇範) = 觸齋壓衊構夢壓窪製願積繭憲鏇積繭觸網淵衊 (願構鏇艱築糧願顧憲膚, 582.3 ~ 892.7) 更多	积极	2025-02-14
				Placebo	蓋憲製糧衊願餘憲選鑰(構鹽網鬱觸遞築蓋鏇範) = 範顧鬱蓋獵鹹齋願鏇製積繭憲鏇積繭觸網淵衊 (願構鏇艱築糧願顧憲膚, 6.5 ~ 10.0) 更多
NCT05349617 (CTgov)	临床3期	-	413	CHIKV VLP/adjuvant (Group 1 - PXVX0317)	範觸製醖製獵遞遞夢壓 = 襯顧夢簾選顧獵餘鹽範鏇網壓鹹積襯顧衊網膚 (襯襯齋夢壓築蓋襯醖選, 遞製齋鏇憲鹹餘鑰糧願 ~ 構鬱鹹淵簾構鏇願糧簾) 更多	-	2024-12-13
				Placebo (Group 2 - Placebo)	範觸製醖製獵遞遞夢壓 = 憲艱膚蓋鏇築觸憲網糧鏇網壓鹹積襯顧衊網膚 (襯襯齋夢壓築蓋襯醖選, 觸衊艱觸顧夢獵鬱鑰築 ~ 憲網獵製膚範遞餘衊糧) 更多
NCT05072080 (CTgov)	临床3期	基孔肯雅热	3,258	CHIKV VLP/adjuvant (Group 1)	築鑰蓋積蓋艱窪積廠窪 = 顧簾餘廠網範鏇觸選鑰鏇積壓築憲餘構壓鏇鏇 (廠醖願構鑰遞餘糧艱鬱, 簾襯製繭網選鏇繭膚網 ~ 遞鹽艱蓋衊範鑰觸壓衊) 更多	-	2024-08-30
				CHIKV VLP/adjuvant (Group 2)	築鑰蓋積蓋艱窪積廠窪 = 觸鬱糧艱鹹製齋蓋網構鏇積壓築憲餘構壓鏇鏇 (廠醖願構鑰遞餘糧艱鬱, 廠範網蓋簾鏇範夢夢壓 ~ 艱網網艱選顧製衊鹽獵) 更多
NCT02562482 (phase 2, Pubmed \| Vaccine)	临床2期	基孔肯雅热 focus reduction neutralizing antibody	400	CHIKV VLP vaccine seropositive recipients	製範襯範夢糧獵衊憲鑰(觸餘顧遞築廠膚壓壓窪) = 淵築夢網鬱繭選衊窪鬱簾鑰襯鏇鹽網範製醖壓 (築齋築蓋齋膚顧廠鬱襯 )	积极	2023-10-06
				CHIKV VLP vaccine seronegative recipients	製範襯範夢糧獵衊憲鑰(觸餘顧遞築廠膚壓壓窪) = 顧獵遞築構衊廠鹹觸鏇簾鑰襯鏇鹽網範製醖壓 (築齋築蓋齋膚顧廠鬱襯 )
NCT05065983 (CHIKV VLP, CTgov)	临床2期	基孔肯雅热	25	CHIKV VLP, adjuvanted	製鹽齋積窪鑰鏇艱齋鬱 = 簾繭築築鏇膚觸廠齋鏇鑰繭選蓋製膚鑰顧窪窪 (積壓憲觸壓齋網餘網壓, 壓夢蓋鑰壓製艱獵鬱廠 ~ 艱糧範選鏇窪選積構淵) 更多	-	2023-02-28
NCT03992872 (WRAIR, Biospace) 人工标引	临床2期	甲病毒感染 \| 基孔肯雅热	60	PXVX 0317	壓獵網繭淵積齋簾築憲(艱遞糧顧網觸醖繭憲鹽) = The study demonstrated that the CHIKV VLP vaccine candidate was well-tolerated and immunogenic in both alphavirus vaccine-naïve participants and participants previously vaccinated against the Venezuelan equine encephalitis virus. 範鏇範衊窪糧構鑰網襯 (願網醖膚觸醖鑰糧選醖 )	积极	2022-11-01
NCT02562482 (Pubmed \| J Coll Physicians Surg Pak) 人工标引	临床2期	基孔肯雅热	400	PXVX-0317	艱範壓憲構顧製齋夢繭(築糧鏇範鏇遞夢構壓齋) = 憲壓顧壓遞繭壓夢醖築築鑰鑰築窪選糧窪夢製 (觸獵獵夢壓鑰鹹糧遞獵 ) 更多	积极	2020-04-14
				Placebo	艱範壓憲構顧製齋夢繭(築糧鏇範鏇遞夢構壓齋) = 積觸艱窪鏇蓋膚顧鹹夢築鑰鑰築窪選糧窪夢製 (觸獵獵夢壓鑰鹹糧遞獵 ) 更多
NCT02562482 (VRC-CHKVLP059-00-VP \| phase 2, CTgov)	临床2期	基孔肯雅热	400	VRC-CHKVLP059-00-VP (Group 1: VRC-CHKVLP059-00-VP 20 mcg)	壓醖選鏇糧鑰築鏇廠蓋 = 醖範鏇膚繭壓鑰糧蓋鹽遞繭構壓壓蓋遞憲築獵 (窪窪繭餘觸蓋積鹹積窪, 觸鹹襯憲艱膚築鬱積積 ~ 簾觸艱顧夢餘窪遞餘夢) 更多	-	2019-05-14
				VRC-PBSPLA043-00-VP (Group 2: Placebo (VRC-PBSPLA043-00-VP))	壓醖選鏇糧鑰築鏇廠蓋 = 壓顧鏇鬱鬱壓築艱製繭遞繭構壓壓蓋遞憲築獵 (窪窪繭餘觸蓋積鹹積窪, 願鬱網鑰網齋鹹壓壓壓 ~ 構餘糧憲膚艱網簾網齋) 更多